BRAUN
11.5.2021 09:02:07 CEST | Business Wire | Press release
Braun celebrates its 100th anniversary in 2021 and we are pleased to announce the 21st BraunPrize International Design Competition, with a virtual awards ceremony due to take place in October 2021.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210511005118/en/
Established in 1968, the BraunPrize was Germany’s first international competition with the aim to promote the work of young designers. Braun’s continuous commitment to this cause has been highly regarded by the design world and the design-aware public ever since.
This year, young, up-and-coming designers and inventors will be tasked with exploring good design to address and solve the challenges of today and tomorrow; and Braun’s commitment to nurturing young talent will see this year’s total prize value increase to $100,000 USD.
A recent global study, conducted by Braun of 18-25 year olds, revealed that Gen Z believes that good design will play a pivotal role in its future. In fact, 4 out of 5 (78%) agreed that accessibility—regardless of age, impairments or skill level—and ease of use are the single most important areas in which design can deliver an impactful change. Simple and useful design means good design for everyone—design that anyone can understand and anyone can make use of to better their life and to better our collective future.
Braun has shaped the past, present and future with ‘good design’. Braun believes that good design follows the principles of ‘Simple, Useful and Built to last,’ and that these design tenents remain as relevant in 2021 as they were in 1921 in making life better for people and the environment. Braun knows that the next 100 years will be shaped through the power of ‘good design’ for our collective benefit, so the 2021 BraunPrize International Design Competition will challenge creative minds to help shape tomorrow.
Oliver Grabes, Head of Braun Design and Chairman of the BraunPrize commented:
“The 2021 BraunPrize International Design Competition challenge is an opportunity for young designers, inventors and students to identify design ideas and visionary concepts that will help promote behavioral change and make an impact on today’s society and the future of our planet. Design that can effect this type of positive social impact is good design at its best.
Oliver continued: “We are really excited by this year’s competition and encourage you to help us shape tomorrow. 2018 saw more submissions than ever, with 3,087 entrants from 107 counties, making it a record year for the BraunPrize. We can’t wait to see what the 2021 BraunPrize International Design Competiton will unearth.”
For more information, please visit www.uk.braun.com/en-gb/braunprize or on Instagram @braunprize.
THE 2021 BRAUN PRIZE INTERNATIONAL DESIGN COMPETITION DETAILS
THE 2021 CHALLENGE: SHAPE TOMORROW
A call to action to help shape tomorrow. A forum for young designers, inventors and students with a commitment to exploring good design to address and solve the challenges of today and tomorrow.
WHO IS ELIGIBLE
The 2021 BraunPrize International Design Competition is open globally and is free to enter. Submissions are welcome from young designers and inventors with less than 5 years work experience and students of any profession.
PRIZE MONEY
The BraunPrize International Design Competition will award $100,000 USD in prize money.
JURY PANEL
The 2021 BraunPrize Internation Design Competition Jury Panel will comprise of international design leaders from across the globe.
SUBMISSION
Submissions for the 2021 BraunPrize International Design Competition will open in July 2021 and the BraunPrize Winner announcements will take place in October 2021.
NOTES TO EDITORS
- The BraunPrize was established in 1968
- The BraunPrize 2021 marks the 21st edition of the international design competition
- In 2018, the BraunPrize received 3,087 entries from 107 countries
- The BraunPrize 2021 is organized by Braun, a Procter & Gamble brand, and managed by the Braun Design Team in Kronberg, Germany
- Braun, a subsidiary of Procter & Gamble founded in Germany in 1921, develops and manufactures a wide variety of small domestic appliances that marry technical innovation, reliable quality and distinctive design. These range from electric shavers and beauty products to hair care appliances. Braun products enjoy worldwide distribution. Please visit www.braun.com for the latest news and in-depth information about the Braun brand.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210511005118/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom